Evidence map›Paper›PMID 29725530›Full record

ArticleMolecular and clinical oncology2018

Long-acting muscarinic antagonist and long-acting β2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery.

Takashi Makino, Hajime Otsuka, Yoshinobu Hata, Satoshi Koezuka, Yoko Azuma, Kazutoshi Isobe, Keishi Sugino, Satoru Ebihara, Sakae Homma, Akira Iyoda

Registry-linked trialOpen access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07543601 (Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07543601 narecruitingnot on this mapstarted 2026, after this paper: background citation

Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention

TypeinterventionalSponsorDitte Krag-HansenRan2026 to 2027Enrolled280ConditionsCOPD (Chronic Obstructive Pulmonary Disease), Lung Cancer (Diagnosis), Lung Neoplasm Malignant, Lung CarcinomaArmsTailored COPD consultations
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis.International journal of chronic obstructive pulmonary disease · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Takashi MakinoDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Hajime OtsukaDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Yoshinobu HataDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Satoshi KoezukaDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Yoko AzumaDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Kazutoshi IsobeDivision of Respiratory Medicine, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Keishi SuginoDivision of Respiratory Medicine, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Satoru EbiharaDepartment of Rehabilitation Medicine, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Sakae HommaDivision of Respiratory Medicine, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Akira IyodaDivision of Chest Surgery, Toho University School of Medicine, Ota, Tokyo 143-8541, Japan.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchodilators are essential for the perioperative management of patients with chronic obstructive pulmonary disease (COPD) undergoing surgery for lung cancer. The objective of the present study was to examine whether the usage of a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) could optimize preoperative lung function and reduce the risk for postoperative pulmonary complications. Thirty-two consecutive patients with moderate-to-severe COPD who underwent a lobectomy for lung cancer and received preoperative LAMA (n=19) or LAMA/LABA (n=13) therapy between January 2005 and December 2015 were enrolled in this retrospective study. The improvement of preoperative pulmonary function and the postoperative morbidity were compared between the patients with preoperative LAMA, and LAMA/LABA therapy. Increases in the forced expiratory volume in one second (FEV

Indexed as

bronchodilatorchronic obstructive pulmonary diseaselong-acting muscarinic antagonistlong-acting β2-agonistlung cancersurgery

Identifiers

PMID29725530
PMCPMC5920355
OpenAlexW2792669527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.